Biotech entity
pharma is the sole category represented across all 1 tracked stories. Alison Moore is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 9 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Mar 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Alison Moore is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 9 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention NXT 41, all published on March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NXT 41. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
NXT 41 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
